Core Viewpoint - Nutex Health Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 8, 2024, and August 14, 2025 [1][2]. Summary by Sections Class Action Details - The lawsuit aims to recover losses for investors affected by false statements and concealment of facts related to Nutex's financial practices [1]. - Allegations include that HaloMD, a third-party vendor, engaged in fraudulent activities that led to unsustainable revenue for Nutex [2]. - The company is accused of overstating its remediation of internal control weaknesses and improperly accounting for stock-based compensation obligations [2]. Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require any out-of-pocket costs for class members [3]. Firm Background - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [4]. - The firm is recognized as one of the top securities litigation firms in the United States, ranking in ISS Securities Class Action Services' Top 50 Report for seven consecutive years [4].

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][2] Group 1: Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant financial losses [1][2] - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract outsized reimbursements [2][3] - The complaint argues that Nutex's revenue model is unstable and that financial statements misrepresented the company's operations [2] Group 2: Market Reaction - Following a report by activist short-seller Blue Orca Capital, Nutex shares dropped over 10%, reflecting investor concerns about the company's reliance on arbitration reimbursements [3][4] - After Nutex announced a delay in its Form 10-Q filing, shares plunged 16.39%, closing at $92.91 [6] Group 3: Financial Reporting Issues - The lawsuit asserts that Nutex misrepresented its progress in addressing internal control deficiencies, particularly in misclassifying stock-based compensation obligations [5] - On August 21, Nutex disclosed that its Audit Committee found prior financial statements required restatement due to incorrect classification of obligations [7] Group 4: Investor Impact - The class-action suit seeks damages for investors who acquired Nutex securities during the alleged misrepresentation period, claiming public disclosures were materially misleading [9] - Hagens Berman is investigating whether Nutex's business model relied on questionable arbitration tactics and if its financial reporting misled investors [10]

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the specified Class Period from August 8, 2024, to August 14, 2025 [8]. Allegation Details - The lawsuit claims that Nutex engaged in a scheme to defraud insurance companies through HaloMD, leading to unsustainable revenue [3]. - It is alleged that Nutex overstated its ability to remediate material weaknesses in its internal controls over financial reporting [3]. - The company reportedly misclassified stock-based compensation obligations, increasing the risk of failing to file timely financial reports with the SEC [3]. - Overall, the public statements made by Nutex were deemed materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Nutex shares and suffered losses are encouraged to contact the law firm for more information regarding their rights and potential claims [4]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 21, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a recognized law firm specializing in representing individual and institutional investors in complex litigation [5].

Core Points - The Gross Law Firm has issued a notice to shareholders of Nutex Health Inc. regarding a class action lawsuit related to misleading statements and financial reporting issues [1][2] - The class period for the lawsuit is from August 8, 2024, to August 14, 2025, during which the company allegedly engaged in fraudulent activities through a third-party vendor, HaloMD [2] - Shareholders are encouraged to register for the class action by the deadline of October 21, 2025, to potentially become lead plaintiffs [3] Allegations Summary - The complaint alleges that Nutex Health Inc. made materially false and misleading statements, including the fraudulent conduct of HaloMD in defrauding insurance companies [2] - It is claimed that revenues from HaloMD's engagement were unsustainable due to the fraudulent nature of the activities [2] - The company reportedly overstated its ability to remediate weaknesses in its internal controls over financial reporting, leading to improper accounting of stock-based compensation obligations [2] Next Steps for Shareholders - Shareholders who purchased shares during the specified class period should register to receive updates and monitor the case's progress [3] - There is no cost or obligation for shareholders to participate in the class action [3] Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices [4] - The firm seeks recovery for investors who suffered losses due to false or misleading statements that inflated stock prices [4]

Core Insights - Nutex Health Inc. reported significant year-over-year growth in patient volume and cash collections for Q3 2025, indicating strong operational momentum and financial performance [1][8]. Financial Performance - Estimated patient volume for Q3 2025 increased to 46,293, representing an 11.1% growth compared to Q3 2024 [2]. - Cash collections for Q3 2025 reached $235,003, reflecting a substantial increase of 258.8% year-over-year [2]. - Year-to-date (YTD) patient volume for 2025 was 140,135, up 14.0% from 2024, while YTD cash collections totaled $546,003, marking a 176.9% increase [2]. Operational Highlights - The growth in patient volume was attributed to strategic facility expansion and increased demand for community-based acute care services [8]. - Enhanced revenue cycle management, improved payer mix, and higher patient acuity contributed to the surge in cash collections [8]. Compliance and Audit Progress - The company is actively working to meet Nasdaq's listing standards and has submitted a plan to regain compliance following a non-compliance notice due to errors in previously issued financial statements [6][7]. - Nutex Health anticipates filing its delinquent Form 10-Q for the period ended June 30, 2025, by December 12, 2025, as part of its compliance efforts [9].

Core Viewpoint - A class action lawsuit has been filed against Nutex Health Inc. for allegedly making materially false and misleading statements regarding its business operations and financial prospects during the Class Period from August 8, 2024, to August 14, 2025 [3][8]. Allegation Details - The lawsuit claims that Nutex engaged in a scheme to defraud insurance companies through HaloMD, leading to unsustainable revenue [3]. - It is alleged that Nutex overstated its ability to remediate material weaknesses in its internal controls over financial reporting [3]. - The company reportedly misclassified stock-based compensation obligations, increasing the risk of failing to file timely financial reports with the SEC [3]. - Overall, the public statements made by Nutex were deemed materially false and misleading throughout the relevant period [3]. Next Steps - Investors who purchased Nutex shares and suffered losses are encouraged to contact the law firm for more information and to discuss their rights [4][8]. - The deadline for investors to apply to be appointed as lead plaintiff in the lawsuit is October 21, 2025 [8]. About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in complex litigation [5].

Core Viewpoint - Nutex Health Inc. is facing legal scrutiny due to a class-action lawsuit alleging deceptive billing practices that artificially inflated its financial results [1][10] Group 1: Legal Allegations - The lawsuit claims Nutex collaborated with HaloMD to submit ineligible insurance claims, misleading shareholders and causing significant losses [1][2] - Allegations include a systematic effort to exploit the insurance arbitration process, submitting thousands of questionable claims to extract outsized reimbursements [2][4] - The revenue model of Nutex is described as unstable, with financial statements failing to accurately reflect the company's operations [3] Group 2: Market Reaction - Following the release of a report by Blue Orca Capital, which accused HaloMD of a fraudulent scheme, Nutex shares dropped over 10% [4][5] - After Nutex announced a delay in its Form 10-Q submission, shares plunged 16.39%, closing at $92.91 [7] Group 3: Financial Reporting Issues - The lawsuit asserts that Nutex misrepresented its progress in addressing internal control deficiencies, particularly in misclassifying stock-based compensation obligations [6] - On August 21, Nutex disclosed that its Audit Committee determined certain prior financial statements required restatement due to incorrect classifications [8] Group 4: Investor Impact - The class-action suit seeks to recover damages for investors who acquired Nutex securities during the alleged misrepresentation period [10][11] - Plaintiffs argue that the company's public disclosures were materially misleading, leading to significant investor harm when the true financial condition was revealed [11]

Core Viewpoint - Nutex Health Inc. is facing a class action securities lawsuit due to alleged securities fraud that occurred between August 8, 2024, and August 14, 2025, impacting investors adversely [1][2]. Summary by Sections Class Action Details - The lawsuit aims to recover losses for investors affected by false statements and concealment of information regarding Nutex's financial practices and relationships with third-party vendors [2]. - Allegations include that HaloMD, a vendor, engaged in fraudulent activities that led to unsustainable revenue for Nutex, and that the company overstated its ability to address internal control weaknesses [2]. Next Steps for Investors - Investors who suffered losses during the specified timeframe have until October 21, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years and consistently ranking among the top securities litigation firms in the U.S. [4].

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) HaloMD, a third-party IDR vendor, was achieving lucrative arbitration results for Nutex by engaging in a coordinated scheme to defraud insurance companies; (ii) as a result, to the extent that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it h ...

Core Viewpoint - Nutex Health Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its financial practices and internal controls [3][4]. Summary by Sections Allegations - The lawsuit claims that Nutex Health, through its third-party vendor HaloMD, engaged in fraudulent activities to defraud insurance companies, leading to unsustainable revenue [3]. - It is alleged that Nutex overstated its ability to remediate weaknesses in its internal financial controls, affecting its accounting for stock-based compensation [3]. - The company reportedly misclassified stock-based compensation obligations as equity instead of liabilities, increasing the risk of delayed financial reporting to the SEC [3]. Class Period and Deadlines - The class period for the lawsuit is from August 8, 2024, to August 14, 2025 [3]. - Shareholders are encouraged to register for the class action by October 21, 2025, to participate in potential recovery [4]. Next Steps for Shareholders - Registered shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. - There is no cost or obligation for shareholders to participate in the lawsuit [4]. Law Firm Information - The Gross Law Firm is leading the class action and is recognized for protecting investors' rights against deceit and fraud [5].